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There are indications that both familial ALS and sporadic ALS phenotype and prognosis are partly 
regulated by genetic and  environmental factors, supporting the theory that ALS is a multifactorial 
disease. The aim of this paper was to assess the role of ATXN2 intermediate length repeats in a large 
series of Italian and Sardinian ALS patients and controls carrying a pathogenetic C9ORF72 
GGGGCC hexanucleotide repeat. A total of 1972 ALS cases were identified through the database 
of the Italian ALS Genetic consortium (ITALSGEN), a collaborative effort including 18 ALS 
centers throughout Italy. The study population included: (1) 276 Italian and 57 Sardinian ALS cases 
who carried the C9ORF72 expansion; (2) 1340 Italian and 299 Sardinian ALS cases not carrying 
the C9ORF72 expansion. A total of healthy 1043 controls were also assessed. Most Italian and 
Sardinian cases and controls were homozygous for 22/22 or 23/23 repeats or heterozygous for 22/23 
repeats of the ATXN2 gene. ATXN2 intermediate length repeats alleles (≥28) were detected in 3 
(0.6%) Italian ALS cases carrying the C9ORF72 expansion, in none of the Sardinian ALS cases 
carrying the expansion, in 60 (4.3%) Italian cases not carrying the expansion, and in 6 (2.0%) 
Sardinian ALS cases without C9ORF72 expansion. Intermediate length repeat alleles were found in 
12 (1.5%) Italian controls and 1 (0.84%) Sardinian controls. Therefore, ALS patients with 
C9ORF72 expansion showed a lower frequency of ATXN2 polyQ intermediate length repeats than 
both controls (Italian cases, p=0.137; Sardinian cases, p=0.0001) and ALS patients without 
C9ORF72 expansion (Italian cases, p=0.005; Sardinian cases, p=0.178). In our large study on 
Italian and Sardinian ALS patients with C9ORF72 GGGGCC hexanucleotide repeat expansion, 
compared to age-, gender- and ethnic-matched controls, ATXN2 polyQ intermediate length does not 
represent a modifier of ALS risk, differently from non-C9ORF72 mutated patients. 
 
1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disorder of the central nervous 
system, almost invariably fatal, characterized by a loss of cortical, bulbar and spinal motor neurons. 
In 10-15% of cases it is genetically transmitted (familial ALS, fALS), while in the remaining cases 
it appears sporadically in the population (sporadic ALS, sALS) (Renton et al, 2014). More than 20 
major genes have been related to ALS, the most common in the Caucasian population being 
C9ORF72, SOD1, TARDBP and FUS (Renton et al, 2014). However, there are now indications that 
both familial ALS and sporadic ALS phenotype and prognosis are partly regulated by genetic and  
environmental factors, supporting the theory that ALS is a multifactorial disease (Al Chalabi et al, 
2014).  
ATNX2 intermediate length repeats have been identified as a risk factor for ALS (Neuenschwander 
et al, 2014) and their presence are additionally associated with reduced survival in ALS patients 
(Chiò et al, 2015). More recently, it has been reported that ATXN2 is also a risk factor for ALS 
patients carrying the GGGGCC hexanucleotide repeat in the first intron of the C9ORF72 gene (van 
Blitterswijk et al, 2014a). This gene accounts for 40% of familial ALS and 7% sporadic ALS in 
European and American series (Majounie et al, 2012). Phenotypes associated with this repeat 
expansion include ALS and/or frontotemporal dementia (FTD), psychotic symptoms (hallucinations 
and delusions), and extrapyramidal signs. The wide and heterogeneous symptomatology related to 
C9ORF72 has yet not been fully explained (Roher et al, 2015).  
The aim of this paper was to assess the role of ATXN2 intermediate length repeats in a large series 




A total of 1972 ALS cases were identified through the database of the Italian ALS Genetic 
consortium (ITALSGEN), a collaborative effort including 18 ALS centers throughout Italy. The 
study population included: (1) 276 Italian and 57 Sardinian ALS cases who carried the C9ORF72 
expansion; (2) 1340 Italian and 299 Sardinian ALS not carrying the C9ORF72 expansion. 
2.2 Controls 
The 1043 controls were included in the analysis. This included: (1) 686 regionally-matched, 
unrelated Italian subjects, reported in previous papers (Corrado et al 2011; Conforti et al, 2012). 
These individuals were predominantly blood donors; (2) 243 regionally-matched, unrelated 
Sardinian subjects; (3) 114 matched subjects identified through the patients’ general practitioners 
(population-based controls) (Chiò et al, 2015). 
2.3. Genetic analysis 
Genomic DNA was isolated from peripheral blood lymphocytes using a standard protocol. The 
ATXN2 CAG repeat in exon 1 (NM_002973.3) was amplified using a fluorescent primer and sized 
by capillary electrophoresis on an ABI 3130 genetic analyzer (Applied Biosystem, Foster City, CA, 
USA) (Cancel et al, 1997). As reported in recent guidelines for molecular genetic testing of 
Spinocerebellar Ataxias (SCA), capillary electrophoresis is the preferred method.to size alleles as it 
allows resolution of alleles that are one triplet apart (Sequeiros et al, 2010). As a quality control, 20 
samples have been genotyped in the six laboratories that performed the molecular genetic testing for 
the present study. The results showed a consistent allele assignment for all the samples.  
To compare our findings to those of van Blitterswijk and colleagues (2014a), we used a threshold of 
28 repeats (or greater) as the definition of intermediate size repeats. However, data using a 
threshold of 27 repeats (the most common used cut-off for ATXN2 intermediate length repeats in the 
literature) are reported as supplementary table.  
All ALS cases were also tested for SOD1 (all exons), TARDBP (exon 6), FUS (exons 14 and 15), 
and C9ORF72 using the methodology described elsewhere (Chiò et al, 2012a).  
2.4. Statistical analysis 
The difference between ATXN2 polyQ intermediate length repeats in cases and controls was 
assessed with Fisher’s exact test.  
2.5. Standard protocol approvals and patient consents 
The study was approved by the Ethical committees of participating centers. Patients and controls 
signed a written informed consent. 
 
3. Results 
The demographic and clinical characteristics of patients and controls are reported in Table 1. Most 
Italian and Sardinian cases, as well as most Italian and Sardinian controls, were homozygous for 
22/22 or 23/23 repeats or heterozygous for 22/23 repeats of the ATXN2 gene. ATXN2 intermediate 
length repeats alleles (≥28) were detected in 3 (0.6%) Italian ALS cases carrying the C9ORF72 
expansion, in none of the Sardinian ALS cases carrying the expansion, in 60 (4.3%) Italian cases 
not carrying the expansion, and in 6 (2.0%) Sardinian ALS cases without C9ORF72 expansion. 
Intermediate length repeat alleles were found in 12 (1.5%) Italian controls and 1 (0.84%) Sardinian 
controls. Therefore, ALS patients with C9ORF72 expansion showed a lower frequency of ATXN2 
polyQ intermediate length repeats than both controls (Italian cases, p=0.137; Sardinian cases, 
p=0.0001) and ALS patients without C9ORF72 expansion (Italian cases, p=0.005; Sardinian cases, 
p=0.178). In patients with C9ORF72 expansion the presence of ATXN2 polyQ intermediate length 
repeats did not modify the age at onset of ALS (ATXN2 expanded, 55.8 years [SD 13.7]] vs. non-
expanded, 58.0 years [9.1], p=0.56). 
4. Discussion  
In our large series of Italian and Sardinian ALS patients, we did not find evidence of increased 
occurrence of ATXN2 polyQ intermediate length repeats in patients with C9ORF72 hexanucleotide 
repeat expansion. In contrast, we confirmed that in patients without C9ORF72 expansion ATXN2 
polyQ intermediate length repeats are associated with a higher risk of ALS.    
C9ORF72 GGGGCC expansions have been related to a quite wide spectrum of clinical 
presentations, going from pure ALS to pure FTD, but also including psychotic and extrapyramidal 
signs and symptoms (Rohrer et al, 2015). This wide range of clinical expressions is reflected by 
neuropathological, MRI and PET studies, showing in C9ORF72 patients an extension of TDP43 
pathology extends toward non-motor areas including prefrontal cortex, cingulate cortex, basal 
ganglia and cerebellum (Cooper-Knock et al, 2012; Bede et al, 2013; Cistaro et al, 2014). The 
widespread diffusion of alterations is considered a hallmark of C9ORF72 mutations in 
neuroimaging and functional studies.  
The reasons of the heterogeneous symptom constellation in patients carrying a GGGGCC expansion 
on the first intron of the C9ORF72 gene are still unclear.  All studies up to date have shown that the 
expansion pattern of GGGGCC in different brain areas was not related to the clinical picture and 
that no correlation was found between expansion size in frontal lobe and occurrence of cognitive 
impairment (van Blitterswijk et al, 2013a; Dols-Icardo  et al, 2104; Nordin et al, 2015). 
Another possibility could be an interaction between the presence of C9ORF72 expansion and one or 
more regulatory genes. The presence of mutations of other ALS- and FTD-related genes (GRN, 
MAPT, TARDBP, FUS, SOD1) in patients carrying the C9ORF72 expansion has been reported as 
possible modifiers of patients’ clinical picture (Chiò et al, 2012b; van Blitterswijk et al, 2014b; van 
Blitterswijk et al 2013b). A study on 36 common genetic variants found that three variants were 
significantly associated with age at onset (rs7018487, UBAP1; rs6052771, PRNP; and rs7403881, 
MT-Ie) and six variants were significantly associated with survival after onset (rs5848, GRN; 
rs7403881, MT-Ie; rs13268953, ELP3; the ε4 allele of APOE; rs12608932, UNC13A; and 
rs1800435, ALAD) (van Blitterswijk et al, 2014b). Finally, it has been shown that TMEM106B 
protect C9ORF72 expansion carriers from developing FTD (van Blitterswijk et al., 2014c). 
Our data contrasts a recent publication based on 331 U.S. patients and 376 U.S. controls reporting 
that ATXN2 polyQ intermediate length repeats act as a disease modifier in C9ORF72 carriers (van 
Blitterswijk et al, 2014a). This discrepancy may be explained by (1) the larger size of the control 
cohort in our series, reducing the risk of  false-negative association, and (2) the ethnic-matching of 
patients and controls, avoiding a possible mismatch related to the different frequency of ATXN2 
polyQ intermediate length repeats according to ethnic background (Chiò et al, 2015).  
In our large study on Italian and Sardinian ALS patients with C9ORF72 GGGGCC hexanucleotide 
repeat expansion, compared to age-, gender- and ethnic-matched controls, ATXN2 polyQ 
intermediate length does not represent a modifier of ALS risk, differently from non-C9ORF72 
mutated patients. Our findings highlight the importance of having complete genetic information on 
ALS patients when assessing putative genetic modifiers.  
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Table 1. Clinical characteristics of ALS cases 
 Italian cases (n=1616) Sardinian cases (n=356) 
Gender  (female) 743 (46%) 128 (36%) 
Mean age at onset (years) 61.5 (11.8) 61.3 (11.5) 





Table 2. ATXN2 polyQ intermediate length repeats (<28 vs. ≥28) in C9ORF72 and non-C9ORF72 cases 

















<28 549 2620 1588 114 592 485 663 3212 2073 




0.62 0.0001 - 0.63 0.10 - 0.61 0.0001 - 
 
 
